Gain Therapeutics, Inc. (GANX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gain Therapeutics, Inc. (GANX) trades at $1.85 with AI Score 33/100 (Grade D). Gain Therapeutics, Inc. is a biotechnology company focused on developing therapies for diseases caused by protein misfolding. Market cap: $79.12M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026GANX stock analysis for 2026: Analysts have set a consensus price target of $10.00 for Gain Therapeutics, Inc., suggesting 439.1% upside from the current price of $1.85. The AI MoonshotScore is 33/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GANX: 1/1 perspectives are bearish.
How is this calculated? →Gain Therapeutics, Inc. (GANX) Healthcare & Pipeline Overview
Gain Therapeutics, Inc., a biotechnology firm with a market capitalization of $79.12M, specializes in developing therapies for protein misfolding diseases. Utilizing its Site-Directed Enzyme Enhancement Therapy platform, the company targets rare genetic and neurological disorders, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for GANX?
Gain Therapeutics presents a focused investment opportunity within the biotechnology sector, targeting diseases caused by protein misfolding. The company's SEE-Tx platform offers a unique approach to drug discovery, potentially leading to novel therapies for rare genetic diseases and neurological disorders. Key value drivers include the successful development and commercialization of its pipeline candidates, particularly those targeting Morquio B, GM1 gangliosidosis, and GBA1 Parkinson's. Upcoming catalysts include the progression of these candidates through clinical trials and potential partnerships with larger pharmaceutical companies. The company's relatively small market capitalization ($0.09 billion) suggests significant upside potential if its programs demonstrate clinical efficacy. However, the inherent risks associated with biotechnology investments, including clinical trial failures and regulatory hurdles, should be carefully considered. The company's ability to secure additional funding to support its research and development efforts is also crucial for its long-term success.
Based on FMP financials and quantitative analysis
GANX Key Highlights
- Gain Therapeutics focuses on developing therapies for diseases caused by protein misfolding, addressing a significant unmet need in rare genetic diseases and neurological disorders.
- The company's Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform offers a unique approach to drug discovery by targeting allosteric sites on misfolded proteins.
- Gain Therapeutics' pipeline includes structurally targeted allosteric regulator candidates for diseases such as Morquio B, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.
- The company's market capitalization is $0.09 billion, indicating potential for growth if its programs demonstrate clinical efficacy.
- Gain Therapeutics operates with a team of 23 employees, led by CEO Gene Mack, and is committed to advancing its pipeline through preclinical and clinical development.
Who Are GANX's Competitors?
GANX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GANX's Key Strengths?
- Proprietary SEE-Tx platform for drug discovery.
- Focus on rare diseases with unmet medical needs.
- Experienced management team with expertise in biotechnology.
- Pipeline of structurally targeted allosteric regulator candidates.
What Are GANX's Weaknesses?
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- Early-stage development programs with high risk of failure.
- Small number of employees.
What Could Drive GANX Stock Higher?
- Clinical trial data readouts for lead programs targeting Morquio B and GM1 gangliosidosis.
- Potential strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline into new disease areas.
- Advancement of clinical programs through regulatory approval.
What Are the Key Risks for GANX?
- Financial-distress signal — its Altman Z-Score of -0.32 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could delay or halt the development of its therapies.
- Regulatory hurdles and delays could impact the timeline for commercialization.
- Competition from other biotechnology companies could limit market share.
- Difficulty in securing additional funding could constrain research and development efforts.
What Are the Growth Opportunities for GANX?
- Expansion of Pipeline: Gain Therapeutics has the opportunity to expand its pipeline by identifying new targets and developing additional structurally targeted allosteric regulator candidates. This could involve exploring new disease areas or developing therapies for different protein misfolding disorders. The market for new therapies is substantial, with unmet needs across various rare genetic diseases and neurological disorders. Successful expansion of the pipeline could significantly increase the company's long-term value. The timeline for this growth opportunity is ongoing, as the company continues to invest in research and development.
- Advancement of Clinical Programs: The successful advancement of its current clinical programs represents a significant growth opportunity for Gain Therapeutics. Positive clinical trial results could lead to regulatory approval and commercialization of its therapies, generating substantial revenue. The company's lead programs, targeting Morquio B, GM1 gangliosidosis, and GBA1 Parkinson's, are particularly promising. The timeline for this growth opportunity depends on the progress of clinical trials, with potential for initial data readouts within the next 1-3 years.
- Strategic Partnerships: Gain Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to additional funding, expertise, and resources, increasing the likelihood of success. The company could also collaborate with academic institutions and research organizations to expand its scientific knowledge and capabilities. The timeline for this growth opportunity is ongoing, as the company actively seeks potential partnerships.
- Orphan Drug Designation: Obtaining orphan drug designation for its therapies could provide Gain Therapeutics with significant commercial advantages, including market exclusivity and tax incentives. Orphan drug designation is granted to therapies that treat rare diseases, providing a period of market exclusivity that can protect the company's investment. The company is likely pursuing orphan drug designation for its lead programs, which target rare genetic diseases. The timeline for this growth opportunity depends on regulatory review, with potential for designation within the next 1-2 years.
- Expansion into New Markets: Gain Therapeutics could expand its geographic reach by commercializing its therapies in new markets. This could involve partnering with international distributors or establishing its own sales and marketing infrastructure in key regions. The global market for rare disease therapies is substantial, with significant opportunities in Europe, Asia, and other regions. The timeline for this growth opportunity depends on regulatory approvals and market access considerations, with potential for expansion within the next 3-5 years.
What Opportunities Does GANX Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline into new disease areas.
- Obtaining orphan drug designation for its therapies.
- Advancement of clinical programs through regulatory approval.
What Threats Does GANX Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other biotechnology companies.
- Difficulty in securing additional funding.
What Are GANX's Competitive Advantages?
- Proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform.
- Patent protection for its small molecule therapies.
- Focus on rare diseases with limited competition.
- Expertise in protein misfolding and allosteric modulation.
What Does GANX Do?
Founded in 2017 and based in Bethesda, Maryland, Gain Therapeutics, Inc. is a biotechnology company dedicated to developing therapies for diseases caused by protein misfolding. The company's core technology is its Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform. This platform enables the discovery of allosteric sites on misfolded proteins. Once these sites are identified, Gain Therapeutics develops proprietary small molecules that bind to these sites, restoring proper protein folding and, consequently, treating the underlying disease. Gain Therapeutics is focused on addressing rare genetic diseases and neurological disorders where protein misfolding plays a significant role. The company's pipeline includes structurally targeted allosteric regulator candidates for a range of diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. These programs represent a diverse portfolio of potential therapies aimed at addressing unmet medical needs in these specific disease areas. The company's approach is differentiated by its focus on allosteric modulation, which offers the potential to restore protein function rather than simply inhibiting or replacing the defective protein. This mechanism of action could lead to more effective and durable treatments for patients with these debilitating conditions. Gain Therapeutics operates with a team of 23 employees, led by CEO Gene Mack, and is committed to advancing its pipeline through preclinical and clinical development.
What Products and Services Does GANX Offer?
- Develop therapies for diseases caused by protein misfolding.
- Focus on rare genetic diseases and neurological disorders.
- Utilize their Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform.
- Discover allosteric sites on misfolded proteins.
- Identify proprietary small molecules that bind these sites.
- Restore protein folding and treat disease.
- Develop structurally targeted allosteric regulator candidates.
How Does GANX Make Money?
- Develop proprietary small molecule therapies.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments and royalties on sales of approved therapies.
What Industry Does GANX Operate In?
Gain Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, significant investment, and substantial risk. The industry is driven by the increasing demand for novel therapies to treat a wide range of diseases, including rare genetic disorders and neurological conditions. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying to develop and commercialize innovative treatments. Gain Therapeutics' focus on protein misfolding diseases and its SEE-Tx platform differentiate it from many of its competitors. The global biotechnology market is projected to reach $3.44 trillion by 2030, growing at a CAGR of 12.3% from 2022, indicating significant growth potential for companies operating in this space.
Who Are GANX's Key Customers?
- Patients suffering from rare genetic diseases and neurological disorders.
- Healthcare providers who treat these patients.
- Pharmaceutical companies seeking to expand their portfolios of rare disease therapies.
GANX Valuation & Market Position
With a $79.12M market cap, Gain Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GANX's quantitative score of 33/100 is below the peer average of 87/100.
FY2026 estForward Outlook
Wall Street analysts project Gain Therapeutics, Inc. revenue of about $50K for fiscal 2026, with EPS near $-0.56. The estimate reflects 4 contributing analysts.
F-Score 3/9Financial Health
Gain Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.32 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -22.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.8%, the inverse of the P/E and a quick read on earnings relative to price.
GANX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Gain Therapeutics' future, indicating that management believes in the company's growth potential.
- Community sentiment has shifted positively as recent developments in their drug pipeline have garnered attention from investors.
- Analysts are increasingly optimistic about their innovative approach to treating neurodegenerative diseases, resonating well with market trends.
- The company has been actively engaging with the investor community, leading to heightened interest and discussions around their therapeutic advancements.
Bear Case
- Concerns about the company's ability to deliver on its ambitious timelines have led to skepticism among some investors.
- Recent market volatility has created a cautious atmosphere, with some community members expressing doubts about the sustainability of its current momentum.
- The competitive landscape in biotech is fierce, and there are worries about how Gain Therapeutics will differentiate itself from established players.
- Some investors are wary of the company's funding situation, raising questions about its ability to support ongoing research and development initiatives.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GANX Latest News
No recent news available for GANX.
GANX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GANX.
Price Targets
Consensus target: $10.00
GANX MoonshotScore
What does this score mean?
The MoonshotScore rates GANX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gene Mack
CEO
Gene Mack serves as the Chief Executive Officer of Gain Therapeutics, bringing extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, with a focus on drug development and commercialization. He has a proven track record of building and managing successful teams, as well as securing funding for research and development programs. His expertise spans across multiple therapeutic areas, including rare diseases and neurological disorders. He is responsible for overseeing the company's strategic direction and operations.
Track Record: Under Gene Mack's leadership, Gain Therapeutics has advanced its pipeline of structurally targeted allosteric regulator candidates and secured key partnerships. He has overseen the expansion of the company's research and development programs, as well as the strengthening of its intellectual property portfolio. His strategic decisions have positioned Gain Therapeutics as a leader in the development of therapies for protein misfolding diseases. He is focused on driving the company's growth and creating value for its shareholders.
GANX Healthcare Stock FAQ
What does Gain Therapeutics, Inc. do?
Gain Therapeutics, Inc. is a biotechnology company focused on developing therapies for diseases caused by protein misfolding. The company utilizes its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover allosteric sites on misfolded proteins and identify small molecules that can restore proper protein folding. Their focus is on rare genetic diseases and neurological disorders, where protein misfolding plays a significant role in disease pathology. The company aims to develop and commercialize novel therapies that address unmet medical needs in these areas.
What are the main risks for GANX?
The main risks for Gain Therapeutics include clinical trial failures, regulatory hurdles, competition from other biotechnology companies, and difficulty in securing additional funding. Clinical trial failures could significantly impact the company's pipeline and valuation. Regulatory hurdles and delays could delay the commercialization of its therapies. Competition from larger pharmaceutical companies with greater resources could limit its market share. The company's ability to secure additional funding is crucial for its long-term success, as it relies on external financing to support its research and development efforts.
How does Gain Therapeutics, Inc. navigate regulatory approval processes?
Gain Therapeutics navigates regulatory approval processes by adhering to strict guidelines set by regulatory agencies such as the FDA in the United States. This involves conducting thorough preclinical studies to demonstrate the safety and efficacy of its drug candidates, followed by well-designed clinical trials to further evaluate their potential benefits and risks in humans. The company also focuses on maintaining open communication with regulatory agencies, seeking guidance and feedback throughout the development process to ensure compliance and increase the likelihood of successful approval. Obtaining orphan drug designation, where applicable, can also streamline the approval process and provide market exclusivity.
What revenue streams does Gain Therapeutics, Inc. have in healthcare?
As a clinical-stage biotechnology company, Gain Therapeutics currently does not have any products approved for commercial sale and therefore does not generate revenue from product sales. Its primary revenue streams are currently limited to potential upfront payments, milestone payments, and research funding received through strategic collaborations and partnerships with larger pharmaceutical companies or research institutions. In the future, if its drug candidates are successfully developed and approved, Gain Therapeutics anticipates generating revenue through product sales, licensing agreements, and royalty payments.
What are the key factors to evaluate for GANX?
Gain Therapeutics, Inc. (GANX) holds an AI score of 33/100 (low). Analysts target $10.00 (+439%). Not financial advice.
How frequently does GANX data refresh on this page?
GANX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GANX's recent stock price performance?
Gain Therapeutics, Inc. (GANX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SEE-Tx platform for drug discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GANX overvalued or undervalued right now?
Valuing Gain Therapeutics, Inc. (GANX) requires multiple metrics. Analysts target $10.00 (+439%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.